drugset
drugset / Trial / NCT00250393

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

NCT00250393 ↗

Phase 2 Completed 64 enrolled Kyowa Kirin, Inc.
RandomizedCrossoverDouble-blindTreatment

Summary

To establish the efficacy of 40 mg/day doses of istradefylline for the change in Unified Parkinson's Disease Rating Scale (UPDRS) part-III (Motor examination) score in patients with Parkinson's disease (PD).

Timeline

Start
2005-11
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Istradefylline Small molecule 40 mg —

Indications

Parkinson disease